SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2

Authors

Institutions

Publication Details

Journal
Cellular and Molecular Life Sciences
Published
2025-04-16
DOI
https://doi.org/10.1007/s00018-025-05688-8
Citations
11
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
14.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2

Fen Xu, Piaojian Yu, Hua Liang, Meijun Wang et al.
11 citations
Cellular and Molecular Life Sciences
Diabetes Treatment and Management
14.24
article

SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2

Fen Xu, Piaojian Yu, Hua Liang, Meijun Wang, Mengyin Cai, Xiaoqi Liang, Xiang Cai, Huanyi Cao
article en
11 citations

Abstract

No abstract available for this paper.
Cellular and Molecular Life SciencesVol. 82(1)
Sun Yat-sen University (CN), Hefei University of Technology (CN), The First People's Hospital of Shunde (CN), Guangdong Academy of Medical Sciences (CN), Third Affiliated Hospital of Sun Yat-sen University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Project
Openalex Percentile: Top 1%
Diabetes Treatment and Management
14.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.